JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB141223

Tetracycline hydrochloride, Broad spectrum antibiotic

Be the first to review this product! Submit a review

|

(0 Publication)

MW 480.9 Da, Purity >96%. Broad spectrum antibiotic, displays bacteriostatic activity. Protein synthesis inhibitor, binds to the 30S ribosomal subunit. Antiapoptotic and anti-inflammatory effects. Active in vivo.

View Alternative Names

AI838772, AW493413, BAZ2B_HUMAN, Bromodomain adjacent to zinc finger domain 2B, Bromodomain adjacent to zinc finger domain protein 2B, DINB protein, DINB1, DINP, DKFZp434H071, DKFZp762I0516, DNA damage inducible protein b, DNA polymerase kappa, DinB homolog 1 (E. coli), FLJ11090, FLJ45644, H-L(3)MBT, H-l(3)mbt protein, KIAA0681, L(3)mbt protein homolog, L(3)mbt-like, L3MBT, L3MBTL, LMBL1_HUMAN, Lethal (3) malignant brain tumor l(3, Lethal(3)malignant brain tumor-like protein 1, MGC104252, MGC112732, OTTHUMP00000162897, OTTHUMP00000162898, POLK_HUMAN, POLQ, Polymerase (DNA directed) kappa, RGD1307316, RP24-311F12.2, SCAN1, TYDP, TYDP1_HUMAN, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, WALp4, ZC2HC3, dJ138B7.3, hWALp4, polymerase, DNA, kappa

1 Images
Chemical Structure - Tetracycline hydrochloride, Broad spectrum antibiotic (AB141223)
  • Chemical Structure

Lab

Chemical Structure - Tetracycline hydrochloride, Broad spectrum antibiotic (AB141223)

2D chemical structure image of ab141223, Tetracycline hydrochloride, Broad spectrum antibiotic

Key facts

Purity

>96%

Form

Solid

form

Molecular weight

480.9 Da

Molecular formula

C<sub>2</sub><sub>2</sub>H<sub>2</sub><sub>5</sub>ClN<sub>2</sub>O<sub>8</sub>

PubChem

54683010

Nature

Synthetic

Solubility

Soluble in water to 100 mM

Biochemical name

(2Z,4S,4aS,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione hydrochloride

Biological description

Broad spectrum antibiotic, displays bacteriostatic activity. Protein synthesis inhibitor, binds to the 30S ribosomal subunit. Antiapoptotic and anti-inflammatory effects. Active in vivo.

Canonical smiles

CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl

Isomeric smiles

C[C@@]1(C2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl

InChi

InChI=1S/C22H24N2O8.ClH/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28;/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30);1H/t9?,10-,15-,21+,22-;/m0./s1

InChiKey

YCIHPQHVWDULOY-BZJZLAOJSA-N

IUPAC Name

(4S,4aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TDP1 also known as Tyrosyl-DNA Phosphodiesterase 1 has a molecular mass of approximately 67 kDa and plays an important role in DNA repair by resolving 3'-phospho-DNA adducts such as those formed by topoisomerase 1. It mainly expresses in the nucleus of various human tissues. DNA polymerase kappa also referred to as POLK has a mass of approximately 98 kDa and is involved in translesion DNA synthesis enabling DNA replication past damaged bases. BAZ2B (Bromodomain Adjacent to Zinc Finger Domain 2B) and L3MBTL1 (Lethal 3 Malignant Brain Tumor-Like Protein 1) both have important roles in chromatin remodeling. BAZ2B has a mass of about 215 kDa and is primarily nuclear whereas L3MBTL1 with 82 kDa is associated with both the nucleus and cytoplasm.
Biological function summary

TDP1 resolves DNA strand interruptions during replication and transcription processes functioning as part of the DNA repair machinery. It does not form complexes but often works in conjunction with other repair proteins like XRCC1. DNA polymerase kappa (POLK) acts biologically to bypass DNA lesions contributing specificity to the translesion synthesis pathway. BAZ2B and L3MBTL1 are significant in chromatin structure maintenance and epigenetic regulation. BAZ2B participates in ATP-dependent chromatin remodeling complexes. Meanwhile L3MBTL1 interacts with unmodified histone tails acting as a transcriptional repressor.

Pathways

TDP1 and DNA polymerase kappa cooperate in the DNA damage response pathways including the base excision repair and translesion synthesis pathways. TDP1's collaboration with XRCC1 and PARP1 highlights its involvement in single-strand break repair. BAZ2B and L3MBTL1 play parts in the regulation of signaling pathways that include chromatin modification and the cell cycle. BAZ2B interacts with proteins like BRG1 while L3MBTL1 relates functionally with core module proteins in complexes influencing transcriptional outcomes.

Mutations or malfunctions in TDP1 correlate with neurodegenerative conditions such as spinocerebellar ataxia with axonal neuropathy (SCAN1). Faults in DNA polymerase kappa may contribute to cancer susceptibility especially in conditions like xeroderma pigmentosum as its impaired function can lead to increased mutagenesis. BAZ2B has potential connections to autism spectrum disorders due to its role in neurological development. Also L3MBTL1 links with cancer biology particularly in hematological malignancies through interactions with proteins such as PRC2 that modulate transcription repression in various gene networks.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com